Enviro White.png

Probiotics and Postbiotics ᴺᴱᵂ


NemaLife can radically transform the discovery of novel Pro- and Postbiotics

The probiotic industry faces two major bottlenecks creating an enormous need for category disruptive innovation. First, the functional characterization of novel microbiome bacteria severely lags the ability to culture and identify them. Second, our understanding of the role of microbiome in human health is still in its infancy


Scientific Publications

NemaLife chip: a micropillar-based microfluidic culture device optimized for aging studies in crawling C. elegans

NemaFlex: a microfluidics-based technology for standardized measurement of muscular strength of C. elegans

Effect of cannabidiol on the long-term toxicity and lifespan in the pre-clinical model Caenorhabditis elegans 

Probiotics and Postbiotics FAQ

Can you study the short or long-term health effects of pro- and postbiotics?


Yes! Our probiotics and postbiotics in vivo assays translate well in multiple aspects to mammalian systems. By now several multinational companies recognized the value of using invertebrate models in this space. Our patented technology is unique in that we can measure long-term health effects without generating artifacts that multiwell plate-based assays create,

Can you work with anaerobic microbes?



Yes, A significant portion of the human gut is anaerobic, therefore anaerobic postbiotic strain development has seen significant interest recently. C. elegans, the invertebrate model in our in vivo assay, is a soil-dwelling nematode, therefore it is naturally adapted to low oxygen conditions. We can work with facultative anaerobic probiotic strains and even obligate anaerobic postbiotic strains.

Pollution Monitoring.png